Abstract
Background: Yanghe Huayan Decoction (YHD), a traditional Chinese medicine, is one of the most common complementary medicine currently used in the treatment of breast cancer (BC). It has been recently linked to suppress precancerous lesion and tumor development. The current study sought to explore the role of YHD on trans-endothelium and angiogenesis of BC. Methods: HER2+ BC cells were treated with YHD, Trastuzumab, or the combination in vitro and in vivo to compare the effects of them on trans-endothelium and angiogenesis features. The present study also investigated the potential molecular mechanism of YHD in inhibiting angiogenesis of BC. Results: YHD significantly suppressed the invasion and angiogenesis of BC cells via elevated pAkt signaling. Administration of YHD in vivo also strikingly repressed angiogenesis in tumor grafts. Conclusion: YHD could partially inhibit and reverse tumorigenesis of BC. It also could inhibit Akt activation and angiogenesis in vitro and in vivo. Its effect was superior to trastuzumab. Thus it was suitable for prevention and treatment of BC.
Highlights
Breast cancer (BC) is one of the leading malignancies in women, accounting for ∼25% cases worldwide [1]
To evaluate the impact of Yanghe Huayan Decoction (YHD), trastuzumab, or the combination on trans-endothelium and angiogenesis of breast cancer (BC) cells, we plated human umbilical vein endothelial cell (HUVEC) on upper chamber and performed transwell assay in different groups
YHD suppressed the activation of Akt signaling of BC cells in vitro and in vivo To investigate the potential mechanism by which YHD suppressed tumor trans-endothelium and angiogenesis, we examined the expression of relevant molecules in tumor metastasis and angiogenesis
Summary
Breast cancer (BC) is one of the leading malignancies in women, accounting for ∼25% cases worldwide [1]. It results in ∼1.68 million cases and 522000 deaths per year [1]. Genetic rearragement during tumor metastasis enables cancer cells to acquire resistance to different chemo- and radiotherapy, accounting for the high mortality of advanced BC [3]. Methods: HER2+ BC cells were treated with YHD, Trastuzumab, or the combination in vitro and in vivo to compare the effects of them on trans-endothelium and angiogenesis features. Conclusion: YHD could partially inhibit and reverse tumorigenesis of BC It could inhibit Akt activation and angiogenesis in vitro and in vivo. It was suitable for prevention and treatment of BC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
